Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Therapeutic efficacy of anti-cancer drugs often relies on apoptosis induction.
• Previous work demonstrated a mitochondrial targeting domain (MTD) peptide induces necrosis.
• BH-3 only proteins, like Noxa, are key regulators in apoptosis pathways.

Purpose of the Study:

• To develop and evaluate a novel fusion peptide, TU17:MTD, for targeted cancer therapy.
• To investigate the tumor-homing and cell-killing capabilities of TU17:MTD.
• To compare the efficacy of TU17:MTD with a pro-apoptotic peptide conjugate.

Main Methods:

• Fusion peptide design: combining neuropilin-1 (NRP-1) targeting peptide with MTD.
• In vitro assessment of necrosis induction in cancer cells.
• In vivo studies using mice with subcutaneous CT26 colorectal carcinoma tumors.
• Intravenous administration of TU17:MTD and monitoring of tumor regression and tissue necrosis.
• Blocking studies using anti-NRP-1 antibody to confirm targeting specificity.

Main Results:

• TU17:MTD induced necrosis in cancer cells in vitro.
• Intravenous injection of TU17:MTD caused significant regression of CT26 tumors in mice.
• Necrosis within tumor tissues was confirmed post-TU17:MTD administration.
• TU17:MTD demonstrated superior tumor regression efficacy compared to a pro-apoptotic peptide conjugate (TU17:D(KLAKLAK)2).
• Targeting to NRP-1 was confirmed and could be blocked by anti-NRP-1 antibody.
• Tumor size substantially reduced with no apparent side effects.

Conclusions:

• The pro-necrotic peptide TU17:MTD effectively targets tumors via NRP-1 and induces significant tumor regression.
• TU17:MTD represents a viable alternative strategy for developing targeted anti-cancer agents.
• Targeted induction of necrosis shows potential as a therapeutic modality in cancer treatment.